Feasibility of a prospective, randomised, open-label, int non-inferiority trial to assess the safety of active survei carcinoma in situ â€“ The LORD study

European Journal of Cancer

51, 1497-1510

DOI: 10.1016/j.ejca.2015.05.008

Citation Report

#	Article	IF	Citations
1	How different terminology for ductal carcinoma in situ impacts women's concern and treatment preferences: a randomised comparison within a national community survey. BMJ Open, 2015, 5, e008094.	0.8	46
2	How different terminology for ductal carcinoma in situ (DCIS) impacts women's concern and management preferences: A qualitative study. Breast, 2015, 24, 673-679.	0.9	21
3	Weighing the Benefits and Harms. , 2016, , 51-85.		0
4	Breast Cancer Clinical Trials: Past Half Century Moving Forward Advancing Patient Outcomes. Annals of Surgical Oncology, 2016, 23, 3145-3152.	0.7	5
5	Reply to C. Shah et al. Journal of Clinical Oncology, 2016, 34, 1824-1825.	0.8	0
6	Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women. Breast Cancer Research and Treatment, 2016, 159, 553-563.	1.1	51
7	Feasibility ofÂa prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ â€“ The LORD study. Breast Diseases, 2016, 27, 47-48.	0.0	0
8	Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ Patient Population at Low Risk of Upgrade to Invasive Carcinoma?. Annals of Surgical Oncology, 2016, 23, 3487-3493.	0.7	66
9	Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy. Breast Cancer Research and Treatment, 2016, 156, 517-525.	1.1	54
10	Treatment of low-risk ductal carcinoma in situ: is nothing better than something?. Lancet Oncology, The, 2016, 17, e442-e451.	5.1	57
11	The impact of field cancerization on the extent of duct carcinoma in situ (DCIS) in breast tissue after conservative excision. European Journal of Surgical Oncology, 2016, 42, 1806-1813.	0.5	5
12	Women with Low-Risk DCIS Eligible for the LORIS Trial After Complete Surgical Excision: How Low Is Their Risk After Standard Therapy?. Annals of Surgical Oncology, 2016, 23, 4253-4261.	0.7	40
13	Not all ductal carcinoma in situ is created equal: can we avoid surgery for lowâ€risk ductal carcinoma in situ?. ANZ Journal of Surgery, 2016, 86, 859-860.	0.3	19
14	The distribution of ductal carcinoma in situ (DCIS) grade in 4232 women and its impact on overdiagnosis in breast cancer screening. Breast Cancer Research, 2016, 18, 47.	2.2	60
15	Ductal carcinoma inÂsitu â€“ update on risk assessment and management. Histopathology, 2016, 68, 96-109.	1.6	38
16	Controversies in the Treatment of Ductal Carcinoma in Situ. Annual Review of Medicine, 2017, 68, 197-211.	5.0	66
17	Paradigm Shifts in Breast Care Delivery: Impact of Imaging in a Multidisciplinary Environment. American Journal of Roentgenology, 2017, 208, 248-255.	1.0	15
18	Current controversies in radiotherapy for breast cancer. Radiation Oncology, 2017, 12, 25.	1.2	33

#	Article	IF	Citations
19	What quality-of-life issues do women with ductal carcinoma in situ (DCIS) consider important when making treatment decisions?. Breast Cancer, 2017, 24, 720-729.	1.3	13
20	A qualitative study on a decision aid for breast cancer screening: Views from women and health professionals. European Journal of Cancer Care, 2017, 26, e12660.	0.7	21
21	Tumor thickness and histological features as predictors of invasive foci within preoperatively diagnosed ductal carcinoma in situ. Human Pathology, 2017, 64, 145-155.	1.1	1
22	Current approach and future perspective for ductal carcinoma in situ of the breast. Japanese Journal of Clinical Oncology, 2017, 47, 671-677.	0.6	53
23	The diagnostic challenge of low-grade ductal carcinoma in situ. European Journal of Cancer, 2017, 80, 39-47.	1.3	32
24	Current treatment trends and the need for better predictive tools in the management of ductal carcinoma in situ of the breast. Cancer Treatment Reviews, 2017, 55, 163-172.	3.4	29
25	Computerâ€aided heterogeneity analysis in breast MR imaging assessment of ductal carcinoma in situ: Correlating histologic grade and receptor status. Journal of Magnetic Resonance Imaging, 2017, 46, 1748-1759.	1.9	22
26	Patient-reported outcomes in ductal carcinoma in situ: A systematic review. European Journal of Cancer, 2017, 71, 95-108.	1.3	38
27	Outcomes for Women with Minimal-Volume Ductal Carcinoma In Situ Completely Excised at Core Biopsy. Annals of Surgical Oncology, 2017, 24, 3888-3895.	0.7	13
28	Patterns of care for ductal carcinoma in situ of the breast: Queensland's experience over a decade. Breast, 2017, 35, 169-176.	0.9	5
29	Identifying a subset of patients with DCIS who have a low likelihood of residual disease at surgical excision following a core needle biopsy. Journal of Surgical Oncology, 2017, 116, 213-219.	0.8	3
30	Mucocoele-like lesions: is surgical excision still necessary?. Clinical Radiology, 2017, 72, 992.e1-992.e6.	0.5	8
31	Imaging Features of Patients Undergoing Active Surveillance for Ductal Carcinoma in Situ. Academic Radiology, 2017, 24, 1364-1371.	1.3	11
32	Surgical Upstaging Rates for Vacuum Assisted Biopsy Proven DCIS: Implications for Active Surveillance Trials. Annals of Surgical Oncology, 2017, 24, 3534-3540.	0.7	76
33	Confusion Over Differences in Registration and Randomization Criteria for the LORIS (Low-Risk DCIS) Trial: A Reply. Annals of Surgical Oncology, 2017, 24, 568-569.	0.7	2
34	Factors Associated With Underestimation of Invasive Cancer in Patients With Ductal Carcinoma In Situ. JAMA Surgery, 2017, 152, 1007.	2.2	26
35	Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS). Breast, 2017, 31, 274-283.	0.9	121
36	Mammographic extent of microcalcifications and oestrogen receptor expression affect preoperative breast carcinoma in situ size estimation. Breast Cancer, 2017, 24, 466-472.	1.3	3

#	Article	IF	Citations
37	Changing Dogma and Decreased Collateral Damage in Breast Cancer Care. Annals of Surgical Oncology, 2017, 24, 2801-2803.	0.7	0
38	Wherein the Authors Attempt to Minimize the Confusion Generated by Their Study â€œBreast Cancer Mortality after a Diagnosis of Ductal Carcinoma In Situâ€•by Several Commentators Who Disagree with Them and a Few Who Donâ€™t: A Qualitative Study. Current Oncology, 2017, 24, 255-260.	0.9	3
39	Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ. European Journal of Surgical Oncology, 2018, 44, 429-435.	0.5	62
40	The role of screening mammography in the era of modern breast cancer treatment. Climacteric, 2018, 21, 204-208.	1.1	8
41	Advancements and Personalization of Breast Cancer Treatment Strategies in Radiation Therapy. Cancer Treatment and Research, 2018, 173, 89-119.	0.2	13
42	Interventions are needed to support patientâ€“provider decision-making for DCIS: a scoping review. Breast Cancer Research and Treatment, 2018, 168, 579-592.	1.1	16
44	Modeling Ductal Carcinoma In Situ (DCIS): An Overview of CISNET Model Approaches. Medical Decision Making, 2018, 38, 126S-139S.	1.2	19
45	Radiation therapy after breast conserving surgery increases long-term breast conservation for DCIS patients. Breast, 2018, 37, 179-180.	0.9	2
46	Modern Approaches to the Surgical Management of Malignant Breast Disease. Clinics in Plastic Surgery, 2018, 45, 1-11.	0.7	11
47	Epidemiology and Risk Factors. , 2018, , 23-37.		0
48	Carcinoma in situ of the breast in New South Wales, Australia: Current status and trends over the last 40 year. Breast, 2018, 37, 170-178.	0.9	10
49	Active surveillance of women diagnosed with atypical ductal hyperplasia on core needle biopsy may spare many women potentially unnecessary surgery, but at the risk of undertreatment for a minority: 10-year surgical outcomes of 114 consecutive cases from a single center. Modern Pathology, 2018, 31, 395-405.	2.9	11
50	Opportunities and priorities for breast surgical research. Lancet Oncology, The, 2018, 19, e521-e533.	5.1	36
51	How do we manage overdiagnosis/overtreatment in breast screening?. Clinical Radiology, 2018, 73, 372-380.	0.5	12
52	Radiotherapy for Ductal Cancer In Situ (DCIS) of the Breast. , 2018, , 1-17.		0
53	A prediction model for underestimation of invasive breast cancer after a biopsy diagnosis of ductal carcinoma in situ: based on 2892 biopsies and 589 invasive cancers. British Journal of Cancer, 2018, 119, 1155-1162.	2.9	27
54	Clinical Trials for Ductal Carcinoma In Situ of the Breast. Journal of Mammary Gland Biology and Neoplasia, 2018, 23, 293-301.	1.0	9
55	Dichotomous histopathological assessment of ductal carcinoma in situ of the breast results in substantial interobserver concordance. Histopathology, 2018, 73, 923-932.	1.6	21

#	Article	IF	Citations
56	Molecular Biology of Breast Cancer. , 2018, , 569-588.		6
57	Ductal Carcinoma In Situ. Surgical Clinics of North America, 2018, 98, 725-745.	0.5	10
58	Prise en charge des carcinomes mammaires in situÂ: surtraitementÂ? Peut-on faire moinsÂ?. Imagerie De La Femme, 2018, 28, 144-151.	0.0	0
59	Breast cancerâ€"related deaths according to grade in ductal carcinoma in situ: A Dutch populationâ€"based study on patients diagnosed between 1999 and 2012. European Journal of Cancer, 2018, 101, 134-142.	1.3	14
60	Are we overtreating intraductal papillomas?. Journal of Surgical Research, 2018, 231, 387-394.	0.8	20
61	Intraoperative Radiation Therapy (IORT): A Series of 1000 Tumors. Annals of Surgical Oncology, 2018, 25, 2987-2993.	0.7	32
62	Breast-conserving therapy for primary Ductal Carcinoma in Situ in The Netherlands: A multi-center study and population-based analysis. Breast, 2018, 42, 3-9.	0.9	9
63	Renaming low risk conditions labelled as cancer. BMJ: British Medical Journal, 2018, 362, k3322.	2.4	31
64	Management and 5-year outcomes in 9938 women with screen-detected ductal carcinoma in situ: the UK Sloane Project. European Journal of Cancer, 2018, 101, 210-219.	1.3	52
65	Local recurrence outcomes after breast conserving surgery and adjuvant radiotherapy in ductal carcinoma in situ of the breast and a comparison with ECOG E5194 study. Breast, 2018, 42, 10-14.	0.9	9
66	It is time to personalize local treatment options for women with â€œgood riskâ€•DCIS. Breast Journal, 2018, 24, 231-232.	0.4	0
67	Using deep convolutional neural networks to identify and classify tumor-associated stroma in diagnostic breast biopsies. Modern Pathology, 2018, 31, 1502-1512.	2.9	145
68	Mathematical Models for Tumor Growth and the Reduction of Overtreatment. Journal of Neurological Surgery, Part B: Skull Base, 2019, 80, 072-078.	0.4	6
69	Not All Ductal Carcinomas In Situ Are Created IDLE (Indolent Lesions of Epithelial Origin). Archives of Pathology and Laboratory Medicine, 2019, 143, 99-104.	1.2	5
70	Reliability of preoperative breast biopsies showing ductal carcinoma in situ and implications for non-operative treatment: a cohort study. Breast Cancer Research and Treatment, 2019, 178, 409-418.	1.1	16
71	Ductal Carcinoma In Situ Management: All or Nothing, or Something in between?. Current Breast Cancer Reports, 2019, 11, 190-202.	0.5	0
72	Surgical management of ductal carcinoma in situ of the breast: A large retrospective study from a single institution. Breast Journal, 2019, 25, 1143-1153.	0.4	7
73	Mammographic Breast Screening in Older Women. , 2019, , 15-36.		0

#	Article	IF	Citations
74	Ductal carcinoma in situ: to treat or not to treat, that is the question. British Journal of Cancer, 2019, 121, 285-292.	2.9	168
75	Salivary metabolomics with alternative decision tree-based machine learning methods for breast cancer discrimination. Breast Cancer Research and Treatment, 2019, 177, 591-601.	1.1	53
76	DCIS with Microinvasion: Is It In Situ or Invasive Disease?. Annals of Surgical Oncology, 2019, 26, 3124-3132.	0.7	36
77	Quality of DCIS information on the internet: a content analysis. Breast Cancer Research and Treatment, 2019, 177, 295-305.	1.1	8
78	Value-Based Radiology in Breast Imaging. Medical Radiology, 2019, , 125-142.	0.0	0
79	ASO Author Reflections: Contralateral Prophylactic Mastectomyâ€"Moving Beyond Sociodemographic Factors. Annals of Surgical Oncology, 2019, 26, 834-835.	0.7	0
81	National consensus recommendations on patient-centered care for ductal carcinoma in situ. Breast Cancer Research and Treatment, 2019, 174, 561-570.	1.1	8
82	Ductal carcinoma in situ of breast: update 2019. Pathology, 2019, 51, 563-569.	0.3	43
83	Qualitative Radiogenomics: Association Between BI-RADS Calcification Descriptors and Recurrence Risk as Assessed by the Oncotype DX Ductal Carcinoma In Situ Score. American Journal of Roentgenology, 2019, 212, 919-924.	1.0	7
84	Ductal Carcinoma In Situ of the Breast. Advances in Surgery, 2019, 53, 21-35.	0.6	3
85	MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial. Lancet Oncology, The, 2019, 20, 1136-1147.	5.1	112
86	A Single-Institution Experience in the Preoperative Selection of DCIS Patients for IORT using the ASTRO Consensus Guidelines. Advances in Radiation Oncology, 2019, 4, 253-260.	0.6	4
87	Utility of diagnostic breast excision biopsies during two decades of screening mammography. Breast, 2019, 46, 157-162.	0.9	6
88	Growth Dynamics of Mammographic Calcifications: Differentiating Ductal Carcinoma in Situ from Benign Breast Disease. Radiology, 2019, 292, 77-83.	3.6	19
90	Trends in frequency and outcome of highâ€risk breast lesions at core needle biopsy in women recalled at biennial screening mammography, a multiinstitutional study. International Journal of Cancer, 2019, 145, 2720-2727.	2.3	10
91	Predictors of an Invasive Breast Cancer Recurrence after DCIS: A Systematic Review and Meta-analyses. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 835-845.	1.1	41
92	Management of Ductal Carcinoma In Situ (DCIS) of the Breast: Present Approaches and Future Directions. Current Oncology Reports, 2019, 21, 33.	1.8	31
94	Variability in diagnostic threshold for comedo necrosis among breast pathologists: implications for patient eligibility for active surveillance trials of ductal carcinoma in situ. Modern Pathology, 2019, 32, 1257-1262.	2.9	27

#	Article	IF	Citations
95	Ethics and Breast Cancer. , 2019, , 257-264.		0
96	Behaviour and characteristics of lowâ€grade ductal carcinoma in situ of the breast: literature review and singleâ€centre retrospective series. Histopathology, 2019, 74, 970-987.	1.6	6
97	Cancer Outcomes in DCIS Patients Without Locoregional Treatment. Journal of the National Cancer Institute, 2019, 111, 952-960.	3.0	76
98	Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCIS. American Journal of Surgical Pathology, 2019, 43, 1574-1582.	2.1	17
99	Estimating the magnitude of clinical benefit of local therapy in patients with DCIS. Breast, 2019, 48, S34-S38.	0.9	7
100	Will surgery be a part of breast cancer treatment in the future?. Breast, 2019, 48, S110-S114.	0.9	3
101	Multicentre study of the risk of invasive cancer and use of sentinel node biopsy in women with a preoperative diagnosis of ductal carcinoma in situ. British Journal of Surgery, 2019, 107, 96-102.	0.1	8
102	Variation in the Use of Boost Irradiation in Breast-Conserving Therapy in the Netherlands: The Effect of a National Guideline and Cofounding Factors. Clinical Oncology, 2019, 31, 250-259.	0.6	9
103	Role of contrast-enhanced spectral mammography in the post biopsy management of B3 lesions: Preliminary results. Tumori, 2019, 105, 378-387.	0.6	12
104	Stromal characteristics are adequate prognosticators for recurrence risk in ductal carcinoma in situ of the breast. European Journal of Surgical Oncology, 2019, 45, 550-559.	0.5	14
105	Comparison of Clinical and Pathologic Characteristics of Ductal Carcinoma in Situ Detected on Mammography versus Ultrasound Only in Asymptomatic Patients. Ultrasound in Medicine and Biology, 2019, 45, 68-77.	0.7	14
106	Significant inter- and intra-laboratory variation in grading of ductal carcinoma in situ of the breast: a nationwide study of 4901 patients in the Netherlands. Breast Cancer Research and Treatment, 2019, 174, 479-488.	1.1	30
107	A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast. International Journal of Cancer, 2020, 146, 1189-1197.	2.3	16
108	Preoperative Delays in the Treatment of DCIS and the Associated Incidence of Invasive Breast Cancer. Annals of Surgical Oncology, 2020, 27, 386-396.	0.7	33
109	Duct Ectasia and Periductal Mastitis. Encyclopedia of Pathology, 2020, , 87-89.	0.0	0
110	Can dedicated breast PET help to reduce overdiagnosis and overtreatment by differentiating between indolent and potentially aggressive ductal carcinoma in situ?. European Radiology, 2020, 30, 514-522.	2.3	11
111	Ductal Carcinoma In Situ. Encyclopedia of Pathology, 2020, , 91-101.	0.0	0
112	Ductal Carcinoma In Situ (DCIS) at Breast MRI: Predictors of Upgrade to Invasive Carcinoma. Academic Radiology, 2020, 27, 1394-1399.	1.3	17

#	Article	IF	Citations
113	Stereotactic Vacuum-Assisted Breast Biopsy in Ductal Carcinoma in situ: Residual Microcalcifications and Intraoperative Findings. Breast Care, 2020, 15, 386-391.	0.8	6
114	Value-based Radiology. Medical Radiology, 2020, , .	0.0	3
115	Low-Grade Ductal Carcinoma In Situ. American Journal of Clinical Pathology, 2020, 153, 360-367.	0.4	7
116	Grading Ductal Carcinoma In Situ (DCIS) of the Breast â€“ Whatâ€™s Wrong with It?. Pathology and Oncology Research, 2020, 26, 665-671.	0.9	17
117	Preparing for the Renaissance: Treating Breast Cancer during the COVID-19 Pandemic and Planning for a Safe Re-Emergence to Routine Surgical Care within a Universal Health Care System. Current Oncology, 2020, 27, 163-168.	0.9	7
118	Views of healthcare professionals about the role of active monitoring in the management of ductal carcinoma in situ (DCIS): Qualitative interview study. Breast, 2020, 54, 99-105.	0.9	9
119	The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ. British Journal of Cancer, 2020, 123, 1513-1520.	2.9	4
120	Association Between Time to Operation and Pathologic Stage in Ductal Carcinoma in Situ and Early-Stage Hormone Receptor-Positive Breast Cancer. Journal of the American College of Surgeons, 2020, 231, 434-447e2.	0.2	24
121	Media coverage of calls to rename low-risk cancers: a content analysis. BMJ Open, 2020, 10, e038087.	0.8	2
122	Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study. Breast Cancer Research and Treatment, 2020, 183, 759-770.	1.1	16
123	In situ breast cancerÂincidence patterns in Iceland and differences in ductal carcinoma in situ treatment compared to Sweden. Scientific Reports, 2020, 10, 17623.	1.6	1
124	<scp>B3</scp> lesion upgrade rates in a tertiary Australian breast centre: a 8â€year experience (2012â€“2019). ANZ Journal of Surgery, 2020, 90, 2521-2526.	0.3	6
125	The impact of ductal carcinoma in situ on health services utilization. Breast Cancer Research and Treatment, 2020, 182, 159-168.	1.1	1
126	Grading variation in 2,934 patients with ductal carcinoma in situ of the breast: the effect of laboratory- and pathologist-specific feedback reports. Diagnostic Pathology, 2020, 15, 52.	0.9	6
127	Do Eligibility Criteria for Ductal Carcinoma In Situ (DCIS) Active Surveillance Trials Identify Patients at Low Risk for Upgrade to Invasive Carcinoma?. Annals of Surgical Oncology, 2020, 27, 4459-4465.	0.7	21
128	Invasive breast cancer and breast cancer mortality after ductal carcinoma in situ in women attending for breast screening in England, 1988-2014: population based observational cohort study. BMJ, The, 2020, 369, m1570.	3.0	58
129	Modeling the natural history of ductal carcinoma in situ based on population data. Breast Cancer Research, 2020, 22, 53.	2.2	22
130	Interobserver Variability in Ductal Carcinoma In Situ of the Breast. American Journal of Clinical Pathology, 2020, 154, 596-609.	0.4	17

#	Article	IF	Citations
131	Factors predictive of invasive ductal carcinoma in cases preoperatively diagnosed as ductal carcinoma in situ. BMC Cancer, 2020, 20, 513.	1.1	10
132	Ductal Carcinoma In Situ (DCIS): the Importance of Patient-Reported Outcomes (PRO). Current Breast Cancer Reports, 2020, 12, 90-97.	0.5	1
133	De-Escalating Treatment of Low-Risk Breast Ductal Carcinoma In Situ. Journal of Clinical Oncology, 2020, 38, 1252-1254.	0.8	8
134	The Fight Against Cancer: Are We Winning or Losing?. IEEE Pulse, 2020, 11, 7-12.	0.1	0
135	Ductal carcinoma in situ on digital mammography versus digital breast tomosynthesis: rates and predictors of pathologic upgrade. European Radiology, 2020, 30, 6089-6098.	2.3	7
136	Breast Pathology. , 2020, , 921-1047.		0
137	Treatment of Ductal Carcinoma In Situ: Considerations for Tailoring Therapy in the Contemporary Era. Current Breast Cancer Reports, 2020, 12, 98-106.	0.5	0
138	The impact of patient characteristics and lifestyle factors on the risk of an ipsilateral event after a primary DCIS: A systematic review. Breast, 2020, 50, 95-103.	0.9	7
139	Predicting Upstaging of DCIS to Invasive Disease: Radiologists's Predictive Performance. Academic Radiology, 2020, 27, 1580-1585.	1.3	4
140	Recall and Outcome of Screen-detected Microcalcifications during 2 Decades of Mammography Screening in the Netherlands National Breast Screening Program. Radiology, 2020, 294, 528-537.	3.6	9
141	Analysis of active surveillance as a treatment modality in ductal carcinoma in situ. Breast Journal, 2020, 26, 1221-1226.	0.4	6
142	Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium. Breast Cancer Research and Treatment, 2020, 181, 487-497.	1.1	272
143	Liquid biopsy for the detection of clinical biomarkers in early breast cancer: new insights and challenges. Pharmacogenomics, 2020, 21, 359-367.	0.6	8
144	Noncalcified Ductal Carcinoma In Situ (DCIS): Rate and Predictors of Upgrade to Invasive Carcinoma. Academic Radiology, 2021, 28, e71-e76.	1.3	15
145	The Impact of the COVID-19 Pandemic on Surgical Management of Breast Cancer: Global Trends and Future Perspectives. Oncologist, 2021, 26, e66-e77.	1.9	36
146	Long-term Survival Outcomes of â€˜Low Riskâ€™ Ductal Carcinoma in situ from a Territory-wide Cancer Registry. Clinical Oncology, 2021, 33, 40-45.	0.6	6
147	Performance of a clinical and imaging-based multivariate model as decision support tool to help save unnecessary surgeries for high-risk breast lesions. Breast Cancer Research and Treatment, 2021, 185, 479-494.	1.1	1
148	Collagen Organization in Relation to Ductal Carcinoma In Situ Pathology and Outcomes. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 80-88.	1.1	21

#	Article	IF	Citations
149	Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project. British Journal of Cancer, 2021, 124, 1009-1017.	2.9	29
150	Mixed-Methods Study to Predict Upstaging of DCIS to Invasive Disease on Mammography. American Journal of Roentgenology, 2021, 216, 903-911.	1.0	7
151	Prospective Multicenter Study Validate a Prediction Model for Surgery Uptake Among Women with Atypical Breast Lesions. Annals of Surgical Oncology, 2021, 28, 2138-2145.	0.7	5
152	Nuclear grade and comedo necrosis of ductal carcinoma in situ as histopathological eligible criteria for the Japan Clinical Oncology Group 1505 trial: an interobserver agreement study. Japanese Journal of Clinical Oncology, 2021, 51, 434-443.	0.6	3
153	De-escalating treatment for ductal carcinoma in situ â€“ Has the pendulum swung too far? (Invited) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.7	1
154	Treating (low-risk) DCIS patients: What can we learn from real-world cancer registry evidence?. Breast Cancer Research and Treatment, 2021, 187, 187-196.	1.1	10
155	Breast Cancer Surgery. , 2021, , 99-107.		0
156	Multi-protein spatial signatures in ductal carcinoma in situ (DCIS) of breast. British Journal of Cancer, 2021, 124, 1150-1159.	2.9	11
157	The Multidisciplinary Approach to Breast Cancer Management. , 2021, , 137-156.		0
158	Complete Removal of the Lesion as a Guidance in the Management of Patients with Breast Ductal Carcinoma In Situ. Cancers, 2021, 13, 868.	1.7	9
159	Variability in grading of ductal carcinoma in situ among an international group of pathologists. Journal of Pathology: Clinical Research, 2021, 7, 233-242.	1.3	16
160	Deep learning-based grading of ductal carcinoma in situ in breast histopathology images. Laboratory Investigation, 2021, 101, 525-533.	1.7	20
161	Ductal Carcinoma In Situ and Progression to Invasive Cancer: A Review of the Evidence. Journal of Breast Imaging, 2021, 3, 135-143.	0.5	5
162	Multi-modal imaging of high-risk ductal carcinoma in situ of the breast using C2Am: a targeted cell death imaging agent. Breast Cancer Research, 2021, 23, 25.	2.2	3
163	Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort study. Breast Cancer, 2021, 28, 896-903.	1.3	11
164	National Variations in the Work-Up, Investigation, and Surgical Management of Ductal Carcinoma In Situ of the Breast across Canadian Surgeons. Current Oncology, 2021, 28, 1366-1375.	0.9	1
165	Management of ductal carcinoma in situ with accelerated partial breast irradiation brachytherapy: Implications for guideline expansion. Brachytherapy, 2021, 20, 345-352.	0.2	1
166	DUCHESS: an evaluation of the ductal carcinoma in situ score for decisions on radiotherapy in patients with low/intermediate-risk DCIS. Breast Cancer Research and Treatment, 2021, 188, 133-139.	1.1	6

#	Article	IF	Citations
168	Genomic profiling reveals heterogeneous populations of ductal carcinoma in situ of the breast. Communications Biology, 2021, 4, 438.	2.0	31
169	Clinicopathological Follow-up of Breast DCIS Diagnosed on Biopsies: A Single Institutional Study of 575 Patients. International Journal of Surgical Pathology, 2021, 29, 836-843.	0.4	0
170	Active surveillance as a management option for cervical intraepithelial neoplasia 2: An online experimental study. Gynecologic Oncology, 2021, 161, 179-187.	0.6	6
171	Innovations for the future of breast surgery. British Journal of Surgery, 2021, 108, 908-916.	0.1	10
172	Symptomatic ductal carcinoma in situ (DCIS): Upstaging risk and predictors. Clinical Imaging, 2021, 73, 101-107.	0.8	8
173	Reflecting on 20 years of breast cancer modeling in CISNET: Recommendations for future cancer systems modeling efforts. PLoS Computational Biology, 2021, 17, e1009020.	1.5	9
174	Surgical upstaging rates in patients meeting the eligibility for active surveillance trials. Japanese Journal of Clinical Oncology, 2021, 51, 1219-1224.	0.6	6
175	The management of women with ductal carcinoma in situ of the breast in Australia and New Zealand between 2007 and 2016. ANZ Journal of Surgery, 2021, 91, 1784-1791.	0.3	2
176	Chronological Trends of Breast Ductal Carcinoma In Situ: Clinical, Radiologic, and Pathologic Perspectives. Annals of Surgical Oncology, 2021, 28, 8699-8709.	0.7	2
177	Single-cell evaluation reveals shifts in the tumor-immune niches that shape and maintain aggressive lesions in the breast. Nature Communications, 2021, 12, 5024.	5.8	11
178	Risk Stratification of Ductal Carcinoma In Situ and Texture Analysis of Contrast-Enhanced Breast Magnetic Resonance Imaging. Journal of Computer Assisted Tomography, 2021, Publish Ahead of Print, 843-848.	0.5	1
179	Low-risk DCIS. What is it? Observe or excise?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 21-32.	1.4	9
180	Preferences of Treatment Strategies among Women with Low-Risk DCIS and Oncologists. Cancers, 2021, 13, 3962.	1.7	8
181	Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast. British Journal of Cancer, 2021, 125, 1443-1449.	2.9	6
182	Preoperative Breast MRI for Newly Diagnosed Ductal Carcinoma in Situ: Imaging Features and Performance in a Multicenter Setting (ECOG-ACRIN E4112 Trial). Radiology, 2021, 301, 66-77.	3.6	17
183	Factors involved in treatment decision making for women diagnosed with ductal carcinoma in situ: A qualitative study. Breast, 2021, 60, 123-130.	0.9	2
184	Carcinoma ductal in situ. EMC - GinecologÃa-Obstetricia, 2021, 57, 1-12.	0.0	0
185	Patterns of treatment and outcome of ductal carcinoma in situ in the Netherlands. Breast Cancer Research and Treatment, 2021, 187, 245-254.	1.1	3

#	Article	IF	Citations
186	Current trials to reduce surgical intervention in ductal carcinoma in situ of the breast: Critical review. Breast, 2017, 35, 151-156.	0.9	24
187	The effect of an e-learning module on grading variation of (pre)malignant breast lesions. Modern Pathology, 2020, 33, 1961-1967.	2.9	10
188	De-Escalation of Locoregional Therapy in Low-Risk Disease for DCIS and Early-Stage Invasive Cancer. Journal of Clinical Oncology, 2020, 38, 2230-2239.	0.8	15
189	Patient and provider experiences with active surveillance: A scoping review. PLoS ONE, 2018, 13, e0192097.	1.1	16
190	Neoadjuvant Endocrine Therapy and Delays in Surgery for Ductal Carcinoma in Situ: Implications for the Coronavirus Pandemic. Annals of Surgical Oncology, 2021, 29, 1683.	0.7	2
192	ç²¾å¯†æœæŸ»ã«ãŠã„ã¦ çµŒéŽè¦³å¯Ÿã,'æŽ¨å¥¨ã™ã,‹ã,«ãƒ†ã,´ãƒªãƒ¼ã,'æ¯Žç¢ºã«ã™ã¹ãã§ã,‹. Nihon Nyugan Kenshin Gakkaishi (Journ 81-85.	0.0	0
193	Ductal Carcinoma In Situ. Encyclopedia of Pathology, 2018, , 1-11.	0.0	0
196	<scp>Mouseâ€ŒNtraDuctal</scp> (<scp>MIND</scp>): an in vivo model for studying the underlying mechanisms of <scp>DCIS</scp> malignancy. Journal of Pathology, 2022, 256, 186-201.	2.1	12
197	Advances and controversies in management of breast ductal carcinoma in situ (DCIS). European Journal of Surgical Oncology, 2022, 48, 736-741.	0.5	10
199	Management of non-invasive tumours, benign tumours and breast cancer during the COVID-19 pandemic: recommendations based on a Latin American survey. Ecancermedicalscience, 2020, 14, 1115.	0.6	3
200	Cost-effectiveness of abbreviated-protocol MRI screening for women with mammographically dense breasts in a national breast cancer screening program. Breast, 2022, 61, 58-65.	0.9	10
201	Unresected screen-detected ductal carcinoma in situ: Outcomes of 311 women in the Forget-Me-Not 2 study. Breast, 2022, 61, 145-155.	0.9	12
202	Management of non-invasive tumours, benign tumours and breast cancer during the COVID-19 pandemic: recommendations based on a Latin American survey. Ecancermedicalscience, 2020, 14, 1115.	0.6	5
203	A Model to Predict Upstaging to Invasive Carcinoma in Patients Preoperatively Diagnosed with Low-Grade Ductal Carcinoma In Situ of the Breast. Cancers, 2022, 14, 370.	1.7	6
204	Preneoplastic Low-Risk Mammary Ductal Lesions (Atypical Ductal Hyperplasia and Ductal Carcinoma In) Tj ETQq0 0 0 rgBT /Overlock 10	1.7	3
205	Long-term outcomes of women with large DCIS lesions treated with breast-conserving therapy. Breast Cancer Research and Treatment, 2022, 192, 223-233.	1.1	6
206	Ductal Carcinoma in Situ: State-of-the-Art Review. Radiology, 2022, 302, 246-255.	3.6	30
207	A web-based personalized decision support tool for patients diagnosed with ductal carcinoma in situ: development, content evaluation, and usability testing. Breast Cancer Research and Treatment, 2022, 192, 517-527.	1.1	4

#	Article	IF	Citations
208	â€œIs it cancer or not?â€•A qualitative exploration of survivor concerns surrounding the diagnosis and treatment of ductal carcinoma in situ. Cancer, 2022, 128, 1676-1683.	2.0	6
209	US, Mammography, and Histopathologic Evaluation to Identify Low Nuclear Grade Ductal Carcinoma in Situ. Radiology, 2022, 303, 276-284.	3.6	2
210	Identifying ductal carcinoma in situ cases not requiring surgery to exclude postoperative upgrade to invasive ductal carcinoma. Breast Cancer, 2022, 29, 610-617.	1.3	1
211	Risk-Associated Lesions of the Breast in Core Needle Biopsies. Surgical Pathology Clinics, 2022, 15, 147-157.	0.7	0
212	Treatment of ductal carcinoma in situ: a register-based study of Norwegian women diagnosed between 1995 and 2018. Breast Care, 0, , .	0.8	0
213	Ductal Carcinoma in Situ: Molecular Changes Accompanying Disease Progression. Journal of Mammary Gland Biology and Neoplasia, 2022, 27, 101-131.	1.0	9
214	Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer. Nature Genetics, 2022, 54, 850-860.	9.4	34
215	DCIS: Risk Assessment in the Molecular Era. Seminars in Radiation Oncology, 2022, 32, 189-197.	1.0	6
216	Is loss of p53 a driver of ductal carcinoma in situ progression?. British Journal of Cancer, 2022, 127, 1744-1754.	2.9	1
217	Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk. British Journal of Cancer, 0, , .	2.9	5
218	Prediction Models and Decision Aids for Women with Ductal Carcinoma In Situ: A Systematic Literature Review. Cancers, 2022, 14, 3259.	1.7	5
219	Molecular signatures of in situ to invasive progression for basal-like breast cancers: An integrated mouse model and human DCIS study. Npj Breast Cancer, 2022, 8, .	2.3	4
220	Impact of Surgical Delay on Tumor Upstaging and Outcomes in Estrogen Receptor-Negative Ductal Carcinoma in Situ Patients. Journal of the American College of Surgeons, 0, Publish Ahead of Print, .	0.2	2
221	Factors influencing the initiation of adjuvant endocrine therapy in patients with estrogen receptor-positive ductal carcinoma in situ: a single institution experience. Breast Cancer Research and Treatment, 0, , .	1.1	1
222	Oncological safety of active surveillance for low-risk ductal carcinoma in situ â€” a systematic review and meta-analysis. Irish Journal of Medical Science, 0, , .	0.8	0
223	De-Escalating the Management of In Situ and Invasive Breast Cancer. Cancers, 2022, 14, 4545.	1.7	5
224	Clinical Trials in Breast Cancer. Surgical Clinics of North America, 2023, 103, 17-33.	0.5	0
225	Prediction of the histologic upgrade of ductal carcinoma in situ using a combined radiomics and machine learning approach based on breast dynamic contrast-enhanced magnetic resonance imaging. Frontiers in Oncology, 0, 12, .	1.3	5

#	Article	IF	Citations
226	Breast diseases. , 2023, , 311-344.e7.		0
227	Changes in breast cancer treatment during the COVID-19 pandemic: a Dutch population-based study. Breast Cancer Research and Treatment, 2023, 197, 161-175.	1.1	5
228	Future Role of Molecular Profiling in Small Breast Samples and Personalised Medicine. , 2022, , 895-915.		0
229	Complete Surgical Excision Is Necessary following Vacuum-Assisted Biopsy for Breast Cancer. Current Oncology, 2022, 29, 9357-9364.	0.9	3
230	Identifying Good Candidates for Active Surveillance of Ductal CarcinomaIn Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort. Cancer Research Communications, 2022, 2, 1579-1589.	0.7	1
231	Cohort profile of the Sloane Project: methodology for a prospective UK cohort study of >15 000 women with screen-detected non-invasive breast neoplasia. BMJ Open, 2022, 12, e061585.	0.8	3
232	Identifying recurrences and metastasis after ductal carcinoma inâ€‰situ (<scp>DCIS</scp>) of the breast. Histopathology, 2023, 82, 106-118.	1.6	3
233	Intraductal delivery of nanocarriers for ductal carcinoma in situ treatment: a strategy to enhance localized delivery. Nanomedicine, 2022, 17, 1871-1889.	1.7	2
234	DCIS: When is accelerated partial breast irradiation an option? A meta-analysis on outcomes and eligibility. American Journal of Surgery, 2023, 225, 871-877.	0.9	0
235	Comment on: Cryoablation Without Excision for Low-Risk Early-Stage Breast Cancer: 3-Year Interim Analysis of Ipsilateral Breast Tumor Recurrence in the ICE3 Trial. Annals of Surgical Oncology, 2023, 30, 3284-3285.	0.7	1
236	Everybody needs good neighbours: the progressive DCIS microenvironment. Trends in Cancer, 2023, 9, 326-338.	3.8	5
237	Human Ductal Carcinoma In Situ: Advances and Future Perspectives. Cold Spring Harbor Perspectives in Medicine, 2023, 13, a041319.	2.9	1
238	Cumulative 6-Year Risk of Screen-Detected Ductal Carcinoma In Situ by Screening Frequency. JAMA Network Open, 2023, 6, e230166.	2.8	0
239	Molecular Signatures in Ductal Carcinoma In Situ (DCIS): A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2023, 12, 2036.	1.0	4
240	De-escalation in DCIS Care. Current Breast Cancer Reports, 2023, 15, 58-68.	0.5	0
241	Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk. The Cochrane Library, 2023, 2023, .	1.5	1
242	A low risk of recurrence after breast-conserving surgery for DCIS: A single-institution experience. Cancer Treatment and Research Communications, 2023, 35, 100706.	0.7	1
243	Should low-risk DCIS lose the cancer label? An evidence review. Breast Cancer Research and Treatment, 2023, 199, 415-433.	1.1	2

#	Article	IF	Citations
249	Precision surgery for breast cancer: current trends and future perspectives. Updates in Surgery, 0, , .	0.9	0